Quantitative Data-Driven Deep Dive on Launch Timings
Global Pharmaceutical Company
Client Problem
Accurately determine competitor launch timings for upcoming products across two major immunology indications based on ongoing active and previously completed clinical trials
EmPartners' Approach
We conducted a thorough secondary-research driven landscape assessment of previous and ongoing studies within the relevant therapy area and adjacent indications
This provided us with ranges of recruitment rates, participant numbers, and endpoint timings across study phases (both registrational and non-registrational ), geographies (global vs. regional), and modes of action (e.g., oral vs. injectable)
We additionally leveraged extensive therapeutic area expertise to understand which trials were the most relevant to use as timing benchmarks across different drug modalities and routes of administration
Client Impact
The client received a quantitative, data-driven assessment of potential launch timings for ≥25 upcoming competitor assets (Phase 2 and beyond) across two therapy areas
This analysis was used as a major input for the following year’s strategic brand plan
